The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-03 · 398 (3) · 2695-2715
DOI: 10.1007/s00210-024-03406-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 10.09.2024. Verfasst von Hayder Ridha-Salman und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq. hayder80.ridha@gmail.com. Hauptthemen laut MEDLINE: Psoriasis, Canagliflozin, Anti-Inflammatory Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 224 Literaturangaben. Gefördert von: Self Funded.
Abstract (Originalsprache)
Psoriasis is a life-long immune-mediated dermatosis with thickened, reddish, and flaky skin patches. Canagliflozin is a gliflozin antidiabetic with non-classical remarkable antioxidative, anti-inflammatory, anti-proliferative, and immune-modulating effects. The aim of this study is to examine the probable effects of topical canagliflozin on a mouse model of imiquimod-provoked psoriasis-like dermatitis. The study evaluated 20 Swiss white mice, sorted haphazardly into 4 groups of 5 animals each. Every mouse, with the exception of the control group, had imiquimod applied topically to their shaved backs for 7 days. The control group included healthy mice that were not given any treatment. Mice in the other three groups underwent topical treatment with vehicle (induction group), 0.05% clobetasol propionate ointment (clobetasol group), or 4% canagliflozin emulgel (canagliflozin 4% group) on exactly the same day as imiquimod cream was administered. Topical canagliflozin markedly lowered the intensity of imiquimod-provoked psoriasis eruptions, featuring redness, glossy-white scales, and acanthosis, while also correcting histopathological aberrations. Canagliflozin administration to imiquimod-exposed animals resulted in significantly decreased cutaneous concentrations of inflammatory mediators such as IL-8, IL-17, IL-23, and TNF-α, with raised levels of IL-10. Canagliflozin further lowered proliferative factors involving Ki-67 and PCNA, diminished oxidative indicators such as MDA and MPO, and augmented the activity of antioxidant markers, notably SOD and CAT. Canagliflozin might alleviate the imiquimod-induced animal model of psoriasis, probably thanks to its profound anti-inflammatory, antioxidant, antiangiogenic, and antiproliferative activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq. hayder80.ridha@gmail.com.
- Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
- College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq.
- Pedodontic, Orthodontic and Preventive Department, College of Dentistry, Babylon University, Babylon, Iraq.
ORCID-Profile: Hayder Ridha-Salman
Förderung
- Self Funded
Zitieren
APA
Ridha-Salman, H., Al-Zubaidy, A. A., Abbas, A. H., Hassan, D. M., & Malik, S. A. (2025). The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(3), 2695-2715. https://doi.org/10.1007/s00210-024-03406-y
Vancouver
Ridha-Salman H, Al-Zubaidy AA, Abbas AH, Hassan DM, Malik SA. The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(3):2695-2715. doi:10.1007/s00210-024-03406-y
BibTeX
@article{RidhaSalman2025,
author = {Ridha-Salman, Hayder and Al-Zubaidy, Adeeb Ahmed and Abbas, Alaa Hamza and Hassan, Dhuha M and Malik, Samir A},
title = {The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {3},
pages = {2695--2715},
doi = {10.1007/s00210-024-03406-y}
}
EUVIMED